diacerein has been researched along with Liver Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Aziz, AM; Abdelzaher, WY; Ahmed, AF; Al-Rashed, S; Batiha, GE; Ibrahim, MA; Ibrahim, YF; Welson, NN | 1 |
| Nicolas, P; Padoin, C; Petitjean, O; Tod, M | 1 |
1 review(s) available for diacerein and Liver Dysfunction
| Article | Year |
|---|---|
Clinical pharmacokinetics of diacerein.
Topics: Aged; Animals; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Interactions; Food-Drug Interactions; Humans; Kidney Diseases; Liver Diseases; Osteoarthritis; Time Factors | 1998 |
1 other study(ies) available for diacerein and Liver Dysfunction
| Article | Year |
|---|---|
Diacerein protects rats with liver ischemia/reperfusion damage: Down-regulation of TLR4/ NFκ-B signaling pathway.
Topics: Alanine Transaminase; Animals; Anthraquinones; Anti-Inflammatory Agents; Antioxidants; Down-Regulation; Fatty Acid-Binding Proteins; Liver; Liver Diseases; Male; NF-kappa B; Oxidative Stress; Protective Agents; Rats; Reperfusion Injury; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2021 |